Last reviewed · How we verify
NCT05151159
Prognostic Value of Protein IMP3 Expression in Cervical Cancer
trial testing immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3 in Cervical Carcinoma in 80 participants. Completed in 31 December 2022.
31 December 2013
Quick facts
| Lead sponsor | University of Mostar |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 January 2003 |
| Primary completion | 31 December 2013 |
| Estimated completion | 31 December 2022 |
Drugs / interventions tested
- immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3
Conditions studied
- Cervical Carcinoma — all drugs for Cervical Carcinoma →
Sponsor
University of Mostar
Who can join
Adults 20 to 60, female only, with Cervical Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The results of recent research on cervical cancer and its precancerous lesions have linked the expression of IMP3 protein to cervical dysplasia and the possibility of severe cervical dysplasia (CIN III) progressing to squamous cell carcinoma. A higher expression of IMP3 protein was found in the cytoplasms of severe cervical dysplasia (CIN III) cells and invasive tumor cells compared to CIN I and CIN II change cells. The sensitivity of IMP3 expression in tumor cells was 96%. In preparations that were IMP3 negative, no further monitoring and treatment revealed squamous cell carcinoma. Further analyzes indicated the possibility of determining IMP3 expression on first cervical biopsy specimens in patients with HSIL ( high grade squamous intraepithelial lesion) lesions as a biomarker to detect a subset of patients in whom lesion invasiveness can be expected.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic Value of IMP3 Expression in Squamous Cervical Cancer.
Krešić T, Klarić M, Eminović S, Kolobarić A, et al · · 2024 · PMID 39351768 · DOI 10.1097/pai.0000000000001226
Verify or expand the search:
- PubMed search for NCT05151159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Carcinoma
Currently open trials in the same condition.
- NCT07407647 — Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer · Phase 2 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
- NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
Other University of Mostar trials
Trials by the same sponsor.
- NCT07236424 — Effectiveness of Exercise, Walking, and Education on Mental Health, Mobility and Quality of Life in Elderly Residents of · NA · completed
- NCT07100795 — Vitamin B12, Folic Acid and Vitamin D Status in Women of Reproductive Age · recruiting
- NCT07099586 — Vitamin B12, Folic Acid, and Vitamin D Status in Women of Reproductive Age · recruiting
- NCT06103227 — The Effect of Low Doses of Prednisone on the Prolongation of Pregnancy in Threatened Preterm Birth · Phase 2, PHASE3 · completed
- NCT07085013 — Effectiveness of Personalized Oral Hygiene Education in Medical and Dental Students Over Two Years · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05151159 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Mostar
- Last refreshed: 10 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05151159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing